Abstract
The insulin-like growth factor-1 receptor(IGF-1R) signaling pathway is frequently deregulated in human tumors and is a target of interest for anti-tumor therapy. Roche R1507 is a fully humanized IGF-1R monoclonal antibody. We evaluated the effects of R1507 on the growth of several pancreatic tumor cell lines in vitro and in vivo. We found pancreatic tumor cell lines moderately expressed IGF-1R by qRT-PCR. The growth inhibitory effect of R1507 against several pancreatic cell lines was determined by IC50 value. Combined R1507 and Gemcitabine or 5-FU has superior additive effect to gemcitabine or 5-FU alone. R1507 showed significant survival in the nude mice intraperitoneal dissemination model with Suit-2 cells. In conclusion, R1507, used alone or combined with gemcitabine is a promising anticancer drug on human pancreatic cancer cells.
